Efficacy of Anti-NRP1 and VEGF-A Combination Treatment

	TGD [%]		Δ % TGD	Efficacy (Binary)
	B20	Combo	Combo/B20	By p≤ 0.05
MDA-MB231	50	88	25.04	1
H1299	216	294	24.47	1
SKMES	60	96	22.62	1
HT29	95	115	10.49	1
MV522	81	88	4.13	0
LS174T	87	54	0	0
A549	163	151	0	0

FIG. 1

RNA Expression (qRT-PCR) Correlation with Efficacy of Anti-NRP1 and Anti-VEGF-A Combination Treatment

	stat.rho	p.value
model	0.9566	7.95E-17
Sema3B	-0.8164	2.955E-07
LGALS1	0.7599	1.402E-05
TGFb	0.7499	2.475E-05
ITGa5	0.6744	0.0009
Bv8	0.6663	0.0013
HGF	-0.6613	0.0015
RGS5	-0.6389	0.0036
LGALS7	-0.6228	0.0063
Sema3F	-0.6206	0.0068
Sema3A	0.5988	0.0135
CSF2	0.5953	0.015
Prox1	-0.56	0.0428
PlGF	0.5507	0.05

FIG. 2


TGFb1 Expression in Human Xenografts
Relative Expression
2048
1024
512
256
128
64
32
16
8
4
2
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 3


Bv8 Expression in Human Xenografts
Relative Expression
16
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
(+)
(-)
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 4


Sema3A Expression in Human Xenografts
Relative Expression
16384
8192
4096
2048
1024
512
256
128
64
32
16
8
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 5


PlGF Expression in Human Xenografts
Relative Expression
16384
8192
4096
2048
1024
512
256
128
64
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 6


LGALS1 Expression in Human Xenografts
Relative Expression
2048
1024
512
256
128
64
32
16
8
4
2
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 7


ITGa5 Expression in Human Xenografts
Relative Expression
1024
512
256
128
64
32
16
8
4
2
1
0.5
0.25
0.125
0.0625
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 8


CSF2 Expression in Human Xenografts
Relative Expression
512
256
128
64
32
16
8
4
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 9


Prox1 Expression in Human Xenografts
Relative Expression
256
128
64
32
16
8
4
2
1
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 10


RGS5 Expression in Human Xenografts
Relative Expression
1024
512
256
128
64
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 11


HGF Expression in Human Xenografts
Relative Expression
1024
512
256
128
64
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 12


Sema3B Expression in Human Xenografts
Relative Expression
512
256
128
64
32
16
8
4
2
1
0.5
0.25
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 13


Sema3F Expression in Human Xenografts
Relative Expression
256
128
64
32
16
8
4
2
1
0.5
0
10
20
30
Δ % TGD
MV522
H1299
SKMES
HT29
MDA-MB231
A549
LS174t

FIG. 14



FIG. 15

Efficacy of Anti-VEGF-C and Anti-VEGF-A Combination Treatment

	TGD [%]		Δ % TGD	Efficacy (Binary)
	B20	Combo	Combo/B20	By p≤ 0.05
A549	155	254	38.86	1
MDA-MB231	109	111	1.3	0
H460	188	242	18.72	1
BxPC3	80	99	10.4	0
DLD-1	71.5	75.5	2.18	0
HT29	73	90.5	10.05	0
SKMES	53	78	16.67	0
MV522	74	58	0	0
PC3	22	27	3.95	0

FIG. 16

VEGF-C Efficacy Modeling

	stat.rho	p.value
model	0.895	3.47E-14
VEGF-D	0.941	1.81E-18
FGF2	0.776	1.03E-08
CSF2	-0.736	1.41E-07
VEGF-A	-0.705	7.86E-07
VEGFR3	0.667	4.81E-06
RGS5/CDH5	0.595	8.02E-05
Prox1	-0.582	0.00013
ICAM1	-0.552	0.00032
ESM1	-0.533	0.00056
PlGF	-0.490	0.00177
ITGa5	-0.383	0.01760
TGFb	*-0.498*	*0.0007*
VEGF-C	*0.332*	*0.0296*

FIG. 17



FIG. 18


VEGF-C Expression in Human Xenografts
Relative Expression
13107.2
6553.6
3276.8
1638.4
819.2
409.6
204.8
102.4
51.2
25.6
12.8
6.4
3.2
1.6
0.8
0.4
0.2
0.1
0.05
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 19


VEGF-D Expression in Human Xenografts
Relative Expression
64
32
16
8
4
2
1
0.5
0.25
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 20


VEGFR3 Expression in Human Xenografts
Relative Expression
256
128
64
32
16
8
4
2
1
0.5
0.25
0.125
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 21


FGF2 Expression in Human Xenografts
Relative Expression
512
256
128
64
32
16
8
4
2
1
0.5
0.25
0.125
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 22


CSF2 Expression in Human Xenografts
Relative Expression
65536
32768
16384
8192
4096
2048
1024
512
256
128
64
32
16
8
4
0
10
20
30
40
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 23


ICAM1 Expression in Human Xenografts
Relative Expression
256
128
64
32
16
8
4
2
1
0.5
0.25
0
10
20
30
40
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 24


RGS5/CDH5 Expression Ratio in Human Xenografts
Relative Expression
16
8
4
2
1
0.5
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 25


ESM1 Expression in Human Xenografts
Relative Expression
1024
512
256
128
64
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 26


Prox1 Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 27


PlGF Expression in Human Xenografts
Relative Expression
16384
8192
4096
2048
1024
512
256
128
64
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 28


ITGa5 Expression in Human Xenografts
Relative Expression
2048
1024
512
256
128
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 29


TGFb Expression in Human Xenografts
Relative Expression
2048
1024
512
256
128
64
32
16
8
4
2
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 30

Efficacy of Anti-EGFL7 and Anti-VEGF-A Combination Treatment

	TGD [%]		Δ % TGD
	B20	Combo	Combo/B20
A549	184	184	0
MDA-MB231	101	193	46.1
H460	143.5	229.7	40.25
BxPC3	199.5	302	34.22
SKMES	71	72	0
SW620	155	150	0
H1299	47.8	232	124.6
MV522	62	58	0
PC3	14.4	21.3	6

FIG. 31

EGFL7 Efficacy Modeling

	stat.rho	p.value
model	0.809	5.18E-11
cMet	-0.811	4.33E-11
Sema3B	-0.806	6.77E-11
FGF9	-0.648	2.63E-06
FN1	-0.639	3.97E-06
HGF	-0.637	4.39E-06
MFAP5	-0.606	1.68E-05
EFEMP2	-0.588	3.42E-05
VEGF-C	0.576	5.25E-05
RGS5	-0.575	5.54E-05
NRP1	-0.549	0.00014
FBLN2	-0.540	0.00019
FGF2	-0.518	0.00037
CSF2	0.512	0.00045
PDGF-C	-0.500	0.00064
Bv8	0.499	0.00066
CXCR4	-0.454	0.00221
TNFa	0.426	0.00439

FIG. 32


Sema3B Expression in Human Xenografts
Relative Expression
512
256
128
64
32
16
8
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 33


FGF9 Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0.5
0.25
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 34


HGF Expression in Human Xenografts
Relative Expression
800
400
200
100
50
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 35


VEGF-C Expression in Human Xenografts
Relative Expression
4096
2048
1024
512
256
128
64
32
16
8
4
2
1
0.5
0.25
0.125
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 36


RGS5 Expression in Human Xenografts
Relative Expression
800
400
200
100
50
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 37


NRP1 Expression in Human Xenografts
Relative Expression
160
80
40
20
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 38


FGF2 Expression in Human Xenografts
Relative Expression
1024
512
256
128
64
32
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 39


CSF2 Expression in Human Xenografts
Relative Expression
512
256
128
64
32
16
8
4
2
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 40


Bv8 Expression in Human Xenografts
Relative Expression
16
8
4
2
1
0.5
0.25
0.125
0.0625
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 41


CXCR4 Expression in Human Xenografts
Relative Expression
512
256
128
64
32
16
8
4
2
1
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 42


TNFa Expression in Human Xenografts
Relative Expression
4096
2048
1024
512
256
128
64
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 43


cMet Expression in Human Xenografts
Microarray Signal
8000
4000
2000
1000
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 44


FN1 Expression in Human Xenografts
64000
32000
16000
8000
4000
Microarray Signal
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 45


Fibulin2 Expression in Human Xenografts
8000
4000
2000
1000
Microarray Signal
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3

FIG. 46


Fibulin4 Expression in Human Xenografts
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3
Microarray Signal
4000
2000
1000
0
25
50
75
100
125
150
Δ % TGD

FIG. 47


MFAP5 Expression in Human Xenografts
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
PC3
Microarray Signal
3200
1600
800
0
25
50
75
100
125
150
Δ % TGD

FIG. 48



FIG. 49

Efficacy of Anti-NRP1 and VEGF-A Combination Treatment

	Δ % TGD Combo/B20	Efficacy (Binary) By p≤ 0.05
MDA-MB231	25.04	1
H1299	24.47	1
SKMES	22.62	1
HT29	10.49	1
1050489	15	1
A2780	24.3	1
U87MG	16.7	1
MV522	4.13	0
LS174T	0	0
A549	0	0
Caki-2	0	0

FIG. 50

RNA Expression (qRT-PCR) Spearman rho Correlation with Efficacy of Anti-NRP1 and Anti-VEGF-A Combination Treatment

	TGD		Binary	
	stat.rho	p.value	stat.rho	p.value
Sema3B	-0.8356	<0.0001	-0.7568	<0.0001
TGFb1	0.8323	<0.0001	0.6487	<0.0001
FGFR4	-0.7475	<0.0001	-0.8534	<0.0001
Vimentin	0.6423	<0.0001	0.5406	<0.0001
Sema3A	0.6364	<0.0001	0.6119	<0.0001
PLC	-0.6218	<0.0001	-0.8166	<0.0001
CXCL5	0.3158	0.0188	0.5071	<0.0001
ITGa5	0.5819	<0.0001	0.7131	<0.0001
PlGF	0.5527	<0.0001	0.5291	<0.0001
CCL2	0.5183	<0.0001	0.4619	0.0004
IGFBP4	-0.4891	0.0002	-0.5981	<0.0001
LGALS1	0.484	0.0002	0.5751	<0.0001
HGF	-0.57	<0.0001	-0.687	<0.0001
TSP1	-0.4441	0.0007	-0.6924	<0.0001
CXCL1	0.4902	0.0001	0.6671	<0.0001
CXCL2	0.4222	0.0013	0.5314	<0.0001
Alk1	0.4511	0.0005	0.5682	<0.0001
FGF8	0.3926	0.003		n.s.

FIG. 51


Sema3 Expression in Human Xenografts
Sema3B
Relative Expression
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
3.9x10-03
2.0x10-03
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489
0
10
20
30
Δ % TGD

FIG. 52


TGFb Expression in Human Xenografts
TGFb
Relative Expression
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
3.9x10-03
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489
0
10
20
30
Δ % TGD

FIG. 53


FGFR4 Expression in Human Xenografts
FGFR4
Relative Expression
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
3.9x10-03
2.0x10-03
9.8x10-04
4.9x10-04
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489
0
10
20
30
Δ % TGD

FIG. 54


VIM Expression in Human Xenografts
VIM
Relative Expression
16
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
3.9x10-03
2.0x10-03
9.8x10-04
4.9x10-04
2.4x10-04
1.2x10-04
6.1x10-05
3.1x10-05
1.5x10-05
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489
0
10
20
30
Δ % TGD

FIG. 55


Sema3A Expression in Human Xenografts
Sema3A
Relative Expression
256
128
64
32
16
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 56


PLC Expression in Human Xenografts
PLC
Relative Expression
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
0.0078125
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 57


CXCL5 Expression in Human Xenografts
CXCL5
Relative Expression
256
128
64
32
16
8
4
2
1
0.5
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 58


ITGa5 Expression in Human Xenografts
ITGa5
Relative Expression
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
3.9x10-03
2.0x10-03
9.8x10-04
4.9x10-04
2.4x10-04
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 59


PIGF Expression in Human Xenografts
PIGF
Relative Expression
64
32
16
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 60


CCL2 Expression in Human Xenografts
CCL2
Relative Expression
512
256
128
64
32
16
8
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 61


IGFBP4 Expression in Human Xenografts
IGFBP4
Relative Expression
16
8
4
2
1
0.5
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 62


LGALS1 Expression in Human Xenografts
LGALS1
Relative Expression
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
0.0078125
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 63


HGF Expression in Human Xenografts
HGF
Relative Expression
16
8
4
2
1
0.5
0.25
0.125
0.0625
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 64


TSP1 Expression in Human Xenografts
TSP1
Relative Expression
256
128
64
32
16
8
4
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 65


CXCL1 Expression in Human Xenografts
CXCL1
Relative Expression
128
64
32
16
8
4
2
1
0.5
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 66


CXCL2 Expression in Human Xenografts
CXCL2
Relative Expression
1024
512
256
128
64
32
16
8
4
2
1
0.5
0.25
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 67


Alk1 Expression in Human Xenografts
Alk1
Relative Expression
2
1
0.5
0.25
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 68


FGF8 Expression in Human Xenografts
FGF8
Relative Expression
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
3.9x10-03
0
10
20
30
Δ % TGD
LS174t
A549
MDA-MB231
HT29
SKMES
H1299
MV522
A2780
U87MG
Caki-2
1050489

FIG. 69

FIG. 70

Efficacy of Anti-VEGF-C and Anti-VEGF-A Combination Treatment

Xenografts Set I	Δ % TGD Combo/B20	Efficacy (Binary) By p≤ 0.05
A549	38.86	1
MDA-MB231	1.3	0
H460	18.72	1
BxPC3	10.4	0
DLD-1	2.18	0
HT29	10.05	0
SKMES	16.67	0
MV522	0	0
PC3	3.95	0

Xenografts Set II	Δ % TGI Combo/B20	Efficacy (Binary) By p≤ 0.05
LXFE409	0	0
LXFL1674	3	0
LXFA629	12	1
LXFA737	2	0
LXFA1335	11	0
CXF243	14	1
CXF260	1	0
MAXF583	2	0
MEXF989	0	0
BXF1218	15	1
BXF1352	21	1
SXF463	0	0

VEGF-C Efficacy Modeling

Gene [Tumor]	Xenograft Set I	Xenograft Set II
VEGF-A	-0.51	n.s.
PlGF	-0.65	n.s.
VEGF-C	**0.32**	**0.49 (0.71*)**
VEGF-D	0.72	-0.27
VEGFR3	0.72	n.s.
IL8	**0.55**	**0.53**
CXCL1/2	**0.55/0.62**	**0.65/0.74**
Hhex	-0.61	-0.54
Col4a1/2	-0.58	-0.49
Alk1	-0.54	-0.51
ESM	-0.58	-0.52
Mincle	n.s.	0.62

FIG. 71



FIG. 72


VEGF-C Expression in Human Xenografts
VEGF-C Set I
Relative Expression
4.096
2.048
1.024
0.512
0.256
0.128
0.064
0.032
0.016
0.008
4.0x10-03
2.0x10-03
1.0x10-03
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 73


VEGF-C Expression in Human Xenografts
VEGF-C Set II
Relative Expression
16.384
8.192
4.096
2.048
1.024
0.512
0.256
0.128
0.064
0.032
0.016
0.008
4.0x10-03
2.0x10-03
1.0x10-03
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463

FIG. 74


VEGF-D Expression in Human Xenografts
VEGF-D Set I
Relative Expression
0.25
0.125
0.0625
0.03125
0.015625
7.8x10-03
3.9x10-03
2.0x10-03
9.8x10-04
4.9x10-04
2.4x10-04
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 75


VEGFR3 Expression in Human Xenografts
VEGFR3 Set I
Relative Expression
0.8192
0.4096
0.2048
0.1024
0.0512
0.0256
0.0128
6.4x10-03
3.2x10-03
1.6x10-03
8.0x10-04
4.0x10-04
2.0x10-04
1.0x10-04
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 76


ESM1 Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0.5
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 77


ESM1 Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0.5
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463

FIG. 78


PlGF Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 79


IL8 Expression in Human Xenografts
Relative Expression
65.536
32.768
16.384
8.192
4.096
2.048
1.024
0.512
0.256
0.128
0.064
0.032
0.016
0.008
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 80


IL8 Expression in Human Xenografts
Relative Expression
65.536
32.768
16.384
8.192
4.096
2.048
1.024
0.512
0.256
0.128
0.064
0.032
0.016
0.008
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463

FIG. 81


CXCL1 Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 82


CXCL1 Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463

FIG. 83


CXCL2 Expression in Human Xenografts
Relative Expression
128
64
32
16
8
4
2
1
0.5
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 84


CXCL2 Expression in Human Xenografts
Relative Expression
512
256
128
64
32
16
8
4
2
1
0.5
0.25
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463

FIG. 85


Hhex Expression in Human Xenografts
Relative Expression
6
3
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 86


Hhex Expression in Human Xenografts
Relative Expression
6
3
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463

FIG. 87

FIG. 88


Col4 Expression in Human Xenografts
Collagen IV a1
Relative Expression
32
16
8
4
2
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3
Collagen IV a2
Relative Expression
32
16
8
4
2
0
10
20
30
40
50
Δ % TGD

FIG. 89


Col4 Expression in Human Xenografts
Collagen IV a1
Relative Expression
32
16
8
4
2
0
10
20
Δ % TGI
Collagen IV a2
Relative Expression
32
16
8
4
2
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463


Alk1 Expression in Human Xenografts
Relative Expression
2
1
0.5
0.25
0
10
20
30
40
50
Δ % TGD
A549
MDA-MB231
H460
BxPC3
DLD-1
HT29
SKMES
MV522
PC3

FIG. 90


Alk1 Expression in Human Xenografts
Relative Expression
2
1
0.5
0.25
0
10
20
Δ % TGI
BXF 1352
LXFE 409
LXFL 1674
LXFA 629
CXF 243
MEXF 989
MAXF 583
BXF 1218
CXF 260
LXFA 1335
LXFA 737
SXF 463

FIG. 91



FIG. 92

Efficacy of Anti-EGFL7 and Anti-VEGF-A Combination Treatment

	Δ % TGD Combo/B20	Efficacy (Binary) By p≤ 0.05
A549	0	0
MDA-MB231	46.1	1
H460	40.25	1
BxPC3	34.22	0
SKMES	0	0
SW620	0	0
H1299	124.6	1
MV522	0	0
PC3	6	0
Mx1	12.56	0
OVCAR3	0	0

FIG. 93

EGFL7 Efficacy Modeling

	stat.rho	p.value
model		
Fras1	-0.63	< 0.0001
cMet	-0.56	< 0.0001
Sema3B	-0.65	< 0.0001
FGF9	-0.41	0.0021
FN1	-0.50	< 0.0001
HGF	-0.511	< 0.0001
MFAP5	-0.48	0.0002
EFEMP2	-0.46	0.0004
VEGF-C	0.43	0.0011
CXCL2	0.66	< 0.0001
FBLN2	-0.53	< 0.0001
FGF2	-0.42	0.0016
PDGF-C	0.66	< 0.0001
Bv8	0.47	0.0003
TNFa	0.46	0.0004
Mincle	0.48	0.0002

FIG. 94



FIG. 95


FGF9 Expression in Human Xenografts
Relative Expression
0.8192
0.4096
0.2048
0.1024
0.0512
0.0256
0.0128
6.4x10-03
3.2x10-03
1.6x10-03
8.0x10-04
4.0x10-04
2.0x10-04
1.0x10-04
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
MX1
PC3
OVCAR3

FIG. 96


HGF Expression in Human Xenografts
Relative Expression
8
4
2
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
MX1
PC3
OVCAR3

FIG. 97


VEGF-C Expression in Human Xenografts
Relative Expression
8
4
2
1
0.5
0.25
0.125
0.0625
0.03125
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
MX1
PC3
OVCAR3

FIG. 98


FGF2 Expression in Human Xenografts
Relative Expression
32
16
8
4
2
1
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
MX1
PC3
OVCAR3

FIG. 99



FIG. 100



FIG. 101



FIG. 102



FIG. 103



FIG. 104



FIG. 105



FIG. 106



FIG. 107



FIG. 108



FIG. 109


Mincle Expression in Human Xenografts
Relative Expression
64
32
16
8
4
2
0
25
50
75
100
125
150
Δ % TGD
A549
MDA-MB231
H460
BxPC3
SKMES
SW620
H1299
MV522
MX1
PC3
OVCAR3

FIG. 110